Jim Cramer is ready for another chaotic week of earnings and recommended investors do their full homework before buying. » Read More
Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.
The list of failed bank continues to grow as the FDIC’s troubled bank list currently stands at 416 troubled banks. Wilbur Ross, chairman and CEO of WL Ross & Co. explained that he expects to see further trouble ahead for banks.
Are there any buying opportunities for investors on the horizon? Jeffrey Saut at Raymond James and Douglas Cliggott at Dover Management shared their market oulooks.
The recession has provided a lot of fodder for comic relief. To help you with your watercooler show, here are more than 50 recession jokes—and some advice for how to tell them. On your mark...get set...joke!
The rally on Wall Street fizzled Monday, snapping a four-day streak that sent stocks up more than 4 percent. The Dow ended pretty much flat, while the Nasdaq and S&P 500 shed 0.1 percent.
Dividend yields in the Dow index are down about a quarter of a point since early June and 165 basis points since early March, as equity markets continue to trend higher, pushing yields lower. Here is a look at the dividend yields of all 30 Dow components:
The Dow jumped 150 points off the morning lows. Does this bullish reversal mean you should jump back in?
Stocks got a weak start after the selloff in China but rebounded by midday after a report showed a surprise drop in crude inventories, which sent oil prices — and energy stocks — soaring.
Compared to an average short interest of 2.2% for all Dow components, bets against these three companies stand at around 8%.
Cramer makes the call on viewers' favorite stocks.
The correction may finally be starting: Stocks plunged more than 2% Monday in their worst selloff in 7 weeks. The Nasdaq was the hardest hit, down nearly 3%.
Before I go on vacation for a week I wanted to close the loop and offer some random thoughts on a few things.
OK. I have to put aside the fact that he went to Notre Dame and is a diehard Fighting Irish fan (Go 'SC!), but Regis' trademark rant against Pfizer on "Fast Money" yesterday is too good not to blog it.
Some people may not expect Regis Philbin to be an investor type, but he’s been actively trading since 1983.
Barry James, president of the James Advantage Funds and Hugh Johnson, chairman and CIO of Johnson Illington Advisors discussed their economic outlooks and shared their investment strategies.
Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.
A sigh of relief can be heard by all after two brutal years in the equity markets. But there is something interesting occurring that is gaining little attention. Companies with consistent, stable cash flow, (and not highly leveraged) are underperforming more risky leveraged assets. What's going on?
Daniel Loeb's Third Point fund, with $1.8 billion in assets under management, has had a successful second quarter. In its most recent letter to investors, acquired by CNBC, the hedge fund reports the following returns and holdings.
In sports, it’s important to play defense AND offense. In investing, the same holds true. After months of defensive strategies, consider your overall offensive strategy as we seem to be seeing an apparent turn in the world's economic fortunes.
Following are the week’s biggest winners and losers. Find out why shares of Nike and American Superconductor popped while Exxon Mobil and Pfizer dropped.